Accueil   Diary - News   All news Theranexus et la fondation BBDF annoncent la conclusion d'un accord de licence exclusive et mondiale

Theranexus et la fondation BBDF annoncent la conclusion d’un accord de licence exclusive et mondiale

 

Theranexus and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate
BBDF-101


• The agreement covers the development and marketing of the drug following a single clinical trial due to begin in 2020.
• If successful, this trial could lead directly to the drug's approval.


Lyon, 12 December 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, is pleased to announce the signing of an agreement with Beyond Batten Disease Foundation, granting it a worldwide exclusive license to develop and commercialize the drug candidate BBDF-101 for juvenile Batten disease. 

 

Read the press release